Subclavian carotid transposition for symptomatic subclavian artery stenosis or occlusion. A comparison with the endovascular procedure.

医学 外科 狭窄 锁骨下动脉 血运重建 围手术期 闭塞 血管成形术 锁骨下盗血综合征 经皮 冲程(发动机) 放射科 心肌梗塞 内科学 机械工程 工程类
作者
Enzo Ballotta,Giuseppe Da Giau,Elvira Abbruzzese,E Mion,Renzo Manara,Claudio Baracchini
出处
期刊:PubMed 卷期号:21 (2): 138-44 被引量:20
链接
标识
摘要

Although subclavian-carotid transposition (SCT), among all extrathoracic revascularization procedures, has emerged as the treatment of choice for symptomatic subclavian artery (SA) stenosis or occlusion, some authors advocate percutaneous transluminal angioplasty with stenting as the optimum primary therapy.to assess safety, efficacy and durability of SCT in the treatment of symptomatic SA stenosis or occlusion.review of a prospectively maintained vascular surgical registry.University vascular surgical service.39 patients requiring surgery for symptomatic stenosis or occlusion of the proximal SA from September 1985 to August 1999.SCT.data were collected prospectively from hospital charts and office medical records to determine demographics, risk factors, presenting clinical manifestation, blood pressure differentials, location of the SA lesion and early postoperative outcome. Long-term follow-up was available in all patients. Patency of the revascularization was determined by physical examination and non-invasive laboratory studies.The perioperative mortality and morbidity rates were 2.5% (1 of 39) and 2.5% (1 of 39), respectively. Immediate relief of symptoms was achieved in 100% of cases. Mean follow-up was 6.8 years. Revascularization neither failed during the follow-up period, nor did patients have recurrent symptoms. The overall survival rates at 1, 3, 5 and 10 years were 100%, 100%, 86% and 68%. Overall late mortality rate was 18.4%: no death was stroke related.SCT is a very safe and effective surgical procedure for the treatment of symptomatic SA atherosclerotic disease, ensuring an excellent long-term patency.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
chen_ml完成签到,获得积分10
刚刚
善学以致用应助kiki采纳,获得10
刚刚
玥越发布了新的文献求助20
刚刚
聪慧乐松应助怕黑的亦瑶采纳,获得10
刚刚
YY发布了新的文献求助20
刚刚
山猫完成签到,获得积分10
刚刚
卡皮巴丘完成签到 ,获得积分10
1秒前
1秒前
YYL发布了新的文献求助10
1秒前
1秒前
佳俊完成签到,获得积分10
1秒前
小道無上发布了新的文献求助10
1秒前
1秒前
1秒前
量子星尘发布了新的文献求助10
2秒前
善学以致用应助呆呆采纳,获得10
2秒前
2秒前
我是老大应助积极的裘采纳,获得10
2秒前
Lucas应助kkkkjbbb采纳,获得10
2秒前
科研通AI6.2应助Dub采纳,获得30
2秒前
2秒前
完美世界应助Ryo采纳,获得10
3秒前
3秒前
如是之人完成签到,获得积分10
3秒前
冷酷的语儿完成签到,获得积分10
4秒前
无000完成签到,获得积分10
4秒前
msl2023发布了新的文献求助10
4秒前
5秒前
纪诗筠发布了新的文献求助10
5秒前
一休发布了新的文献求助10
5秒前
痴情的路灯完成签到,获得积分10
5秒前
5秒前
6秒前
6秒前
sharkmelon发布了新的文献求助10
7秒前
gao发布了新的文献求助10
7秒前
7秒前
1234qwer完成签到,获得积分20
7秒前
万能图书馆应助无情半凡采纳,获得10
7秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Handbook of pharmaceutical excipients, Ninth edition 5000
Aerospace Standards Index - 2026 ASIN2026 3000
Polymorphism and polytypism in crystals 1000
Signals, Systems, and Signal Processing 610
Discrete-Time Signals and Systems 610
T/SNFSOC 0002—2025 独居石精矿碱法冶炼工艺技术标准 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 物理 生物化学 化学工程 计算机科学 复合材料 内科学 催化作用 光电子学 物理化学 电极 冶金 遗传学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 6044423
求助须知:如何正确求助?哪些是违规求助? 7811409
关于积分的说明 16245187
捐赠科研通 5190243
什么是DOI,文献DOI怎么找? 2777302
邀请新用户注册赠送积分活动 1760429
关于科研通互助平台的介绍 1643622